NCT01714765View on ClinicalTrials.gov

Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

April 30, 2011

Primary Completion Date

October 31, 2012

Study Completion Date

October 31, 2012

Conditions
Metastatic Clear Cell Renal Cancer
Interventions
DRUG

Dovitinib

Cohort 0: 200mg, Cohort 1: 300mg, Cohort 2: 300mg, Cohort 3: 400mg, Cohort 4: 500mg. Cohort -1: 100mg

DRUG

Everolimus

Cohort 0: 5mg, Cohort 1: 5mg, Cohort 2: 10mg, Cohort 3: 10mg, Cohort 4: 10mg, Cohort -1: 5mg.

Trial Locations (1)

EC1M 7BE

Barts Health NHS Trust, London

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Queen Mary University of London

OTHER